Glycated Chitosan Adjuvant Development Service

Glycated Chitosan (GC) Adjuvant Development Service at CD BioGlyco

With the advanced laboratory and technologies, CD BioGlyco provides a variety of solutions for our Marine Carbohydrate-based Vaccine Development Service and Marine Carbohydrate-based Adjuvant Development Service. Among these, our GC adjuvant development services are specifically as follows:

Immune-enhancing Adjuvant (IEA) Development

The development of GC-based immune-enhancing adjuvants requires several aspects. Firstly, we optimize the binding mode, ratio, and delivery vehicle of glycosylated chitosan and vaccine antigens to improve the immunogenicity and stability of the vaccine. Secondly, we explore how adjuvants regulate the type of immune response, increase cellular and humoral immune responses, and so on. In addition, we evaluate the safety of adjuvants and conduct toxicity studies to ensure the biocompatibility and safety of adjuvants. Finally, the preparation process and production conditions need to be optimized to improve the performance of adjuvants in terms of purity, efficacy, and stability.

Adsorption Adjuvant Development

We modulate the adsorption properties and selectivity of adjuvants by varying the degree of glycosylation and molecular weight of GC. In addition, auxiliary substances such as cross-linkers and additives are also used to improve the stability and lifetime of the adjuvants. The adsorption adjuvants are applied to the removal and purification of pollutants in various fields such as water and air.

Development of Peptide Carrier Adjuvants

By binding peptide drugs to GC to form stable complexes, we protect peptide drugs from enzymatic degradation and rapid clearance, prolong their circulating half-life, and increase the accumulation of peptide drugs on target tissues or cells. We optimize the binding strength and release characteristics between the peptide drug and GC by adjusting the glycosylation degree, molecular weight, and structure of GC. In addition, the peptide drug can also be encapsulated in GC nanoparticles using nanoparticulation technology to improve the stability of the peptide drug and the feasibility of oral administration.

Other Adjuvant Development

Fig.1 Techniques used in the development of GC adjuvants. (CD BioGlyco)

Publication Data

Technology: Immunological assays and chemical modification

Journal: Journal of Immunology Research

IF: 4.493

Published: 2013

Results: This article discusses the role of several substances (chitin, chitosan, and GC) as adjuvants in cancer vaccines for modulating immune responses. The article notes that chitin and chitosan have immunostimulatory activity and have structural similarities to natural polysaccharide adjuvants. These substances can be administered by adherent mucosal routes (e.g., oral, nasal, and ocular) or other routes (e.g., intraperitoneal, intravenous, subcutaneous, and intratumoral). These substances can activate macrophages, natural killer (NK) cells, and other immune cells, induce cytokine and chemokine production and enhance adaptive immune responses. In addition, these substances enhance antigen-specific antibody levels and cell-mediated immune responses. These findings suggest that chitin, chitosan, and GC are potential cancer vaccine adjuvants that could be used to enhance the efficacy of cancer immunotherapy.

Fig.2 Basic structure of GC. (Korbelik, et al., 2015)

Applications

• GC is used as a drug delivery system to encapsulate drugs within it and achieve controlled release of drugs through targeted delivery.
• GC is used to improve drug stability, increase drug bioavailability, and enhance drug uptake and retention in target tissues or cells.
• GC has good biocompatibility and biodegradability, so it can be used to prepare wound dressings.

Advantages

• GC adjuvants are biodegradable and do not accumulate in the body to produce toxic side effects.
• We have extensive technical expertise and experience in the research and development of GC adjuvants, with a deep scientific background and professional knowledge.
• We not only provide GC adjuvant development services, but we also provide a full range of technologies.

CD BioGlyco as a premier service provider in the realm of pharmaceutical discovery and investigation, is fully equipped and committed to delivering comprehensive GC adjuvant development services to our clients. Please contact us if you have any questions regarding our services.